Rationale and Evidence for Individualized Treatment Decisions in gMG

Released On
September 9, 2022

Expires On
September 9, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology, Neurology

Topic(s)
Myasthenia Gravis; Neuromuscular; Rare Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.

 

In collaboration with the National Organization for Rare Disorders, Inc. (NORD) and Myasthenia Gravis Foundation of America, Inc.

This activity is supported by an educational grant from argenx.

Credit Available

  • Physicians — 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The intended audience for this activity are neurology, neuromuscular, neuroimmunology, and neuro-ophthalmology specialists, along with advanced practice neurology practitioners, such as neurology NPs, neurology PAs, and clinical pharmacists.

Program Overview

The treatment paradigm for generalized myasthenia gravis (gMG) is changing rapidly with the availability of new antibody tests and targeted treatment options. The treatment landscape for gMG is shifting from reliance on nonspecific immunosuppressants to personalized targeted approaches that address the underlying pathophysiology and achieve disease remission. More than ever, clinicians must engage their patients with gMG in shared decision-making to ensure treatment selection aligns with patient characteristics, preferences, and goals.

The 60-minute CME-certified activity, “Rationale and Evidence for Individualized Treatment Decisions in gMG,” will review recently approved and emerging treatment options that have shown a more rapid onset of effect and improved disease control than traditional treatments. Expert panelists will review clinically important gMG outcomes measures and compare the safety and efficacy profiles of both current and emerging treatments for patients with gMG.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the burden of gMG disease and its treatment with traditional options
  • Summarize the targeted mechanisms of action, efficacy, safety, and place in therapy of new and emerging treatments for gMG with a focus on FcRn-receptor antagonists
  • Describe how accounting for patient characteristics (autoantibody status, MG presentation), preferences, desire to maintain autonomy, quality of life, and treatment goals can impact treatment selection

Faculty

Name of Faculty or Presenter Reported Financial Relationship
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
School of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Consulting Fee (e.g., Advisory Board): Alexion Pharmaceuticals, argenx, F. Hoffmann-LaRoche Ltd, Immunovant, Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi, US, and Viela Bio Inc (now Horizon Therapeutics)

Contracted Research: Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Millennium Pharmaceuticals, Ra Pharmaceuticals (now UCB)

Honoraria:Alexion Pharmaceuticals, argenx, F. Hoffmann-LaRoche Ltd, Immunovant, Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi, US, Viela Bio Inc (now Horizon Therapeutics)

Stock Option Holder: General Electric, GlaxoSmithKline, Johnson & Johnson, and Pfizer
Nicholas J. Silvestri, MD, FAAN
Associate Professor of Neurology
University at Buffalo Jacobs School of Medicine & Biomedical Sciences
Buffalo, NY
Consulting Fee (e.g., Advisory Board):
Alexion, argenx, Avilar, Immunovant, and UCB
Kimberly Baggett
Patient Panelist
Nothing to disclose

 

The planners and managers have the following relevant financial relationships with ineligible companies:

 

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel, PhD Nothing to disclose
Colleen Hefner Nothing to disclose
Stephanie Puccio Nothing to disclose
Lauren Sinclair Nothing to disclose

 

 

Joint Accreditation Statement

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc. (NORD) and Myasthenia Gravis Foundation of America, Inc.

 

 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

 

The faculty have the following relevant financial relationships with ineligible companies

Name of Faculty or Presenter Reported Financial Relationship
Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC
President Elect-American Society for
Preventative Cardiology
Nothing to disclose
Keith C. Ferdinand , MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in
Preventive Cardiology
Professor of Medicine
Tulane University School of Medicine
Consulting Fee (e.g., Advisory Board):
Amgen, Sanofi, Boehringer Ingelheim,
Novartis, Quantum Genomics, Eli Lilly
Darren McGuire, MD, MHSc
Dallas Heart Ball Chair for Research on
Cardiovascular Analytics, Research, and Data Science (CARDS)
Heart Disease in Women
University of Texas Southwestern Medical Center
Consulting Fee (e.g., Advisory Board):
Lilly USA, Boehringer Ingelheim, Merck &
Co, Novo Nordisk, Applied Therapeutics,
Metavant, Sanofi, Afimmune, CSL
Behring, Bayer, GlaxoSmithKline
Honoraria: Boehringer Ingelheim, Sanofi,
Merck & Co, Pfizer, AstraZeneca, Novo
Nordisk, Esperion, Lilly USA, Lexicon, CSL Behring

 

The planners and managers have the following relevant financial relationships with ineligible companies:

 

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Colleen Hefner Nothing to disclose
Caroline Laurendeau Nothing to disclose

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/